Current medication options to treat opioid use disorders (OUD) approved by the FDA include opioid agonists (methadone, buprenorphine) and antagonist (naltrexone). Since naltrexone does not have reinforcing properties compared to agonists in patients with OUD, lower treatment retention has been noted by clinicians during the last decades and naltrexone has been rarely used. The newly approved long-acting formulation–extended release injectable naltrexone (XR- NTX) promises better compliance than oral naltrexone, given the fact it requires its administration only once a month.
The CSAT-NIDA pre-conference session during the 2015 AATOD Conference brought together clinicians, researchers, and administrators to summarize all three medication options and to compare and contrast their utility in patients with OUD. The session presenters received many questions, mostly on XR-NTX as this modality is still unknown to most of the clinicians. Since the 2015 session provided an introduction and an overall great summary of this topic, the presenters will build upon outcomes and conclusions and focus specifically on new knowledge and data related to two clinical trials using XR-NTX in parolees and CJS-involved persons with a history of OUD and in HIV-infected patients with co-occurring alcohol use disorder (AUD) and/or OUD.
The presenters will also discuss descriptive findings of staff attitudes and behavior related to prescribing XR-NTX from an ongoing study of XR-NTX treatment in adolescents and young adults with OUD. The session attendees will also have a chance to discuss with presenters their clinical experience in managing patients that are interested in treatment with XR-NTX.
Sponsored by the National Institute for Drug Abuse, the National Drug Abuse Treatment Clinical Trials Network (NIDA/CTN)